Red Light Therapy (Photobiomodulation)

Red light therapy — also called photobiomodulation (PBM), low-level laser therapy (LLLT), and low-level light therapy — uses specific wavelengths of red and near-infrared light to stimulate cellular activity. Unlike most regenerative therapies covered on CellIntel, this one has a clearer regulatory path and a broader evidence base.

What the science says

The current model of how red light therapy works involves photons in the 600–1,070 nm range being absorbed by cytochrome c oxidase, a key enzyme in cellular energy production. This stimulates increased ATP production, modulates reactive oxygen species, and influences gene expression related to inflammation and tissue repair [Hamblin, 2017, AIMS Biophysics].

Three things you should know up front:

1. Dose matters. Every published study specifies wavelength (nm), fluence (joules per square centimeter), and exposure time. "Red light" without those parameters is not meaningful. Effective doses vary significantly by tissue and indication.

2. FDA-cleared vs. wellness device. Some red light therapy devices are FDA-cleared (under 510(k)) for specific indications. Most at-home devices marketed for "wellness" are NOT cleared for treatment of any specific condition.

3. "Red light" ≠ "infrared" ≠ "LLLT" ≠ "LED" ≠ "laser." These are often used loosely in marketing but represent different delivery mechanisms with different evidence bases.

FDA regulatory status

As of 2026, FDA 510(k) clearances exist for specific red light / photobiomodulation devices in the following indications:

Important: A device being FDA-cleared for one indication does not mean the therapy is approved for other uses. Marketing claims beyond cleared indications are off-label and subject to FTC enforcement.

The broader claim that "red light therapy treats X" — where X is anything from Parkinson's to long COVID to ADHD — is not FDA-supported. Research may be promising, but the regulatory status of the therapy for those uses is clearly "not FDA-approved."